We are live on ! Find out more

Vaxcyte

PCVX

Market cap $9.16B

61.17 USD

-0.41

0.67%

At close Updated Sep 3, 4:00 PM EDT

Pre-market

After hours

60.41

-0.76

1.24%

1 day

-0.67%

5 days

0.18%

1 month

14.27%

3 months

30.34%

6 months

2.26%

Year to date

31.66%

1 year

90.56%

5 years

138.39%

10 years

133.92%

About: Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Employees: 507

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:

Vaxcyte to Participate in Upcoming Investor Conferences

24/7 Wall Street

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027 Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

See News Rankings

Price charts implemented using Lightweight Charts™